Psoraxine: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 21 patients, Psoraxine was well tolerated at single doses of 50 mg, 150 mg or 300 mg. At day 14, more patients receiving Psoraxine showed i...